All Articles

The strategic merger creates a vertically integrated supplier, combining advanced forming with precision machining to target aerospace, defense, and automotive.

With a massive $200M Series A and a promising Phase 2 drug, new biotech AirNexis aims to reshape the multi-billion dollar COPD treatment landscape.

With a major investment from Santé Ventures, Brado AI is deploying conversational AI to guide patients and ease provider burdens. Here’s what it means.

The oil and gas firm raised its quarterly payout to $0.40/share, rewarding investors and underscoring its financial health and disciplined strategy.

With 11 straight quarters of growth and a focus on 'Physical AI,' lidar leader Ouster is set to detail its ambitious strategy for institutional investors.

A new partnership makes Eli Lilly's powerful AI models available to smaller firms via Revvity's platform, aiming to accelerate innovation with federated learning.

Global investment giant Lone Star Funds acquires a second major office asset in South Florida, signaling strong confidence in the region's booming market.

After a major business sale, Elutia is launching NXT-41x, an antibiotic biomatrix designed to combat the high rate of infection in breast reconstruction.

Rigetti Computing pushes back its Cepheus-1-108Q launch to Q1 2026, a move that rattled investors but underscores the quantum industry's tough race for fidelity.

With its first MASH drug a success, Madrigal aims to redefine treatment by combining it with a newly licensed Pfizer asset. Is this the future?

Koppers Holdings navigates a key leadership change as CFO Jimmi Sue Smith retires. Veteran Bradley Pearce takes the helm as interim financial chief.

The fintech platform grew twice as fast as the overall market in 2025, fueled by tech innovation and a surge in multi-protocol trading adoption.

With a huge new investment, MEDIPOST is advancing its proven stem cell therapy for knee osteoarthritis into a pivotal Phase III trial in the United States.

Aesthetics firm Evolus reports its first profitable quarter and robust growth, banking on new products and international markets to defy industry slowdowns.

A validated study on LEON's FR-JET® mixer shows it creates highly concentrated, potent mRNA nanoparticles, promising to speed up drug development.

As Encompass Health sets its Q4 earnings date, investors watch to see if the rehab giant can sustain its impressive 2025 growth amid industry pressures.

Modest growth is forecast, but Canada's economy faces a pivotal year as federal stimulus clashes with looming CUSMA renegotiations and U.S. headwinds.

As Mammoth Biosciences preps for JPM, its ultracompact CRISPR tech aims to redefine in vivo gene therapy, promising cures for diseases beyond the liver.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.